Adam Bell

Company: Neuraly

Job title: Vice President - Translational Medicine & Regulatory Affairs

Seminars:

DD01 – GLP-1/Glucagon Dual Agonist for the Treatment of MASH 5:00 pm

Developing a once weekly dual agonist of GLP-1 and glucagon receptors Exploring the benefits of half-life extension in obese/overweight patients with type 2 diabetes and MAFLD Assessing the benefits of DD01 in its ability to augment incretin therapy, acting through the glucagon receptor and enhancing liver lipolysis to treat the liver first Read more

day: Day One